adding gentamicin to fluoroquinolone-based antimicrobial prophylaxis reduces transrectal ultrasound-guided prostate biopsy-related infection rate

Clicks: 522
ID: 159498
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #6 of 280 articles by views in acta crystallographica section e

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 280 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Objective: Transrectal ultrasound-guided prostate (TRUS) biopsy is the standard method for the diagnosis of prostate cancer. Quinolone-based prophylaxis before a TRUS biopsy of the prostate is the most common regimen worldwide. In this retrospective study, we evaluated the efficacy and cost effectiveness of adding gentamicin to a fluoroquinolone-based prophylaxis regimen. Materials and methods: In total, our study included 263 patients classified into two groups. Group 1 consisted of 129 patients who received one oral dose of levofloxacin (500 mg) daily 2 days before the biopsy, on the day of the biopsy, and for 2 days after the biopsy. Group 2 consisted of 134 patients who received a single intramuscular (IM) gentamicin injection (80 mg) 30 minutes before the biopsy in addition to the same oral levofloxacin protocol as Group 1. We recorded and analyzed data including age, indication for a TRUS biopsy of the prostate, prostate volume, comorbidity, infectious complications, and blood and urine culture results. Results: The mean prostate-specific antigen level was 38.6 ng/mL ± 312.9 ng/mL (range, 4.4–2626 ng/mL) in Group 1, and 34.8 ng/mL ± 127.1 ng/mL (range, 2.11–1423 ng/mL) in Group 2. The groups were similar in terms of mean age, indication for a biopsy, prostate volume, number of biopsy cores taken, and comorbidities. Infection-related complications occurred in eight of 129 (6.2%) and in one of 134 (0.74%) patients in Groups 1 and 2, respectively (p = 0.02). Conclusion: The addition of IM gentamicin (80 mg) was beneficial in improving the efficacy of fluoroquinolone and reducing the post-TRUS biopsy infection rate. Gentamicin is relatively inexpensive and readily available in daily practice and has good compliance for patient use.
Reference Key
hsieh2016urologicaladding Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Tzuo-Yi Hsieh;Yu-Lin Kao;Shao-Chuan Wang;Wen-Jung Chen;Sung-Lang Chen
Journal acta crystallographica section e
Year 2016
DOI
10.1016/j.urols.2015.04.008
URL
http://www.sciencedirect.com/science/article/pii/S187952261500072X
Keywords
biopsy prostate gentamicin prophylaxis urology quinolonediseases of the genitourinary system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.